Is Axsome Therapeutics (AXSM) Still Below Fair Value On Sales?

Axsome Therapeutics has seen its stock price move sharply over recent years, which naturally raises a question for investors who care about fundamentals. Is the current US$204.07 share price adequately supported by the company’s sales base today and what the market expects those revenues to do over time?

• Over the past 5 years the stock has delivered a very large gain of about 7x, which puts a lot of weight on whether the underlying sales profile can carry that kind of market value.
• The business now depends heavily on how effectively it can convert its commercial pipeline into recurring product revenue, since that will influence the level and durability of sales that investors are effectively paying for.
• There is a second opinion on Axsome Therapeutics worth weighing. See what analysts think Axsome Therapeutics's shares could be worth.

The issue now is whether Axsome Therapeutics’ current market value is appropriately aligned with the sales it is generating and is expected to generate.

If you want to stress test Axsome Therapeutics against similar opportunities, a focused screen of 34 high quality undervalued stocks can be a useful next step in your research.

Is Axsome Therapeutics a Bargain on Sales?

P/S is a useful lens for Axsome Therapeutics because the company is still building toward consistent profitability, so sales are the cleaner anchor for valuation. On this metric, the stock trades on a P/S of 13.8x, compared with a Pharmaceuticals industry average of 5.2x and a peer group around 9.8x. This places Axsome’s valuation toward the upper end of the range investors are paying for similar businesses.

The fair P/S multiple implied by the model, which blends Axsome Therapeutics’ growth outlook, margins, risk profile and size, suggests the current 13.8x is below where the stock might trade if it were valued in line with those fundamentals. That gap points to a price that screens as undervalued on this specific sales-based yardstick. It still leaves plenty for you to weigh around execution on the commercial pipeline and the durability of future revenues before forming a full view. Explore the numbers behind Axsome Therapeutics's P/S valuation.

The Axsome Therapeutics Narrative: What Would Justify Today's Price?

Narratives for Axsome Therapeutics pick up where the P/S puzzle leaves off by spelling out which combinations of future growth, profitability and earnings power would need to hold for the stock to look materially richer or cheaper than today’s price, and they sit on Simply Wall St's Community page. Where a single ratio or valuation output gives one number, these storylines lay out the future that number relies on so you can watch how real-world results compare over time.

One of the top community narratives on Axsome Therapeutics: 28% undervalued

"Diverse CNS product portfolio and late-stage pipeline position company to capitalize on global demand trends while reducing dependence on single products..."

Discover why this Narrative puts Axsome Therapeutics at 28% undervalued.

The price of Axsome Therapeutics is only one piece of your decision

The next question is who is actually steering Axsome Therapeutics and how their pay shapes the choices they make on risk, growth and capital allocation, which you can only judge by looking directly at the details. See who runs Axsome Therapeutics and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com